GlassScriptPhysician profile
Scott R Seals
NPI 1730370875
$2,565.52
in general payments reported to CMS, 2019-2025
39 companies · $581 in 2025
The $581 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $72.18 · 2021: $105 · 2022: $191 · 2023: $590 · 2024: $642 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.79 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $603.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $188.89 | 2019-2025 | Opdivo |
| Pfizer INC. | $173.82 | 2019-2025 | |
| Abbvie INC. | $109.18 | 2023-2024 | Venclexta |
| Merck Sharp & Dohme LLC | $106.84 | 2019-2024 | Lynparza, Keytruda |
| Genzyme Corporation | $104.43 | 2019-2024 | |
| Incyte Corporation | $103.82 | 2019-2025 | Jakafi |
| Gilead Sciences, INC. | $99.83 | 2021-2025 | Trodelvy |
| Amgen INC. | $99.78 | 2019 | |
| Pharmaessentia USA Corporation | $94.41 | 2023-2025 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $92.65 | 2021-2023 | Imbruvica, Epkinly |
| Tempus Ai, INC | $83.59 | 2024-2025 | Xt Cdx |
| Alnylam Pharmaceuticals INC. | $73.66 | 2025 | Givlaari |
| Astellas Pharma US INC | $63.31 | 2022-2025 | Vyloy |
| Ipsen Biopharmaceuticals, INC | $59.47 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $45.40 | 2025 | Xalkori, Lorbrena, Braftovi |
| Kite Pharma, INC. | $43.59 | 2023-2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $40.40 | 2019-2020 | |
| Myovant Sciences INC. | $35.79 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.26 | 2019-2024 | Fruzaqla |
| Glaxosmithkline, LLC. | $33.20 | 2023-2024 | Shingrix, Ojjaara |
| Rigel Pharmaceuticals, INC. | $32.78 | 2023 | Rezlidhia, Tavalisse |
| Cti Biopharma Corp. | $24.36 | 2023 | Vonjo |
| Sumitomo Pharma America, INC. | $21.78 | 2023 | Orgovyx |
| Sobi, INC | $19.99 | 2022 | |
| Eisai INC. | $18.54 | 2024 | |
| Lilly USA, LLC | $18.05 | 2024 | Verzenio |
| Daiichi Sankyo INC. | $17.62 | 2024 | Vanflyta |
| Ge Healthcare | $16.89 | 2022 | |
| Beone Medicines USA, INC. | $16.13 | 2025 | Tevimbra |
| Seagen INC. | $15.47 | 2023 | Adcetris |
| Janssen Biotech, INC. | $15.17 | 2022 | |
| Kyowa Kirin, INC. | $14.53 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.84 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.13 | 2019 | |
| Apo-Pharma USA, INC. | $8.74 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Seals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.